Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03582124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Sep 2026 → Apr 2027
See other at-risk trials from Stanford University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Apr 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 4 entries
  2. Primary completion date: Jan 2026 to Sep 2026
    • Study completion date: Feb 2027 to Sep 2026
    v17
  3. Lead sponsor: Eben Rosenthal to Stanford University
    • Site contact updated
    v16
  4. Primary completion date: Feb 2027 to Jan 2026v15
  5. Trial status: Suspended to Recruiting
    • Enrollment target: 6 to 30
    • Site details revised
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Trial status: Active, Not Recruiting to Suspended Sponsor's reason: Logistics
    • Primary and study completion dates: Sep 30, 2023 to Feb 2027
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Primary completion date: Sep 30, 2021 to Sep 30, 2023
    • Study completion date: Mar 30, 2023 to Sep 30, 2023
    v11
  4. Primary completion date: Jun 30, 2021 to Sep 30, 2021
    • Study completion date: Jun 30, 2021 to Mar 30, 2023
    v10
  5. Trial status: Suspended to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 6
    v9
  6. Trial status: Recruiting to Suspended Sponsor's reason: Logistics
    • Site details revised
    v8
  7. Trial status: Suspended to Recruiting
    • Site details revised
    v7
  8. Re-verified, no change to tracked fieldsv6
  9. Trial status: Recruiting to Suspended Sponsor's reason: Business Decision
    • Site details revised
    v5
  10. Re-verified, no change to tracked fieldsv4
  11. Site contact updatedv3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 30, 2018 to Jul 19, 2018
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stanford University
634 trials monitored
See 47 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.
Trial Details
NCT Number NCT03582124
Lead Sponsor Stanford University
Conditions
(from sponsor)		 Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Related terms Lung Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov